Subcutaneous Immunotherapy Safety: Incidence per Surveys and Risk Factors

Immunol Allergy Clin North Am. 2020 Feb;40(1):25-39. doi: 10.1016/j.iac.2019.09.001.

Abstract

Subcutaneous immunotherapy (SCIT) is effective for allergic rhinitis and conjunctivitis, asthma, and insect venom hypersensitivity. The risk of severe allergic reactions induced by SCIT remains low, and mild systemic reactions have recently shown a tendency to decline. However, near-fatal and fatal anaphylactic reactions may occur. Clinicians administering allergen-specific immunotherapy should receive specialized training and be aware of risk factors and preventive measures to avoid severe allergic reactions induced by SCIT.

Keywords: Allergen immunotherapy; Anaphylaxis; Immunotherapy; Subcutaneous immunotherapy; Venom immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Allergens / immunology*
  • Anaphylaxis / epidemiology*
  • Anaphylaxis / etiology
  • Asthma / epidemiology
  • Asthma / immunology
  • Asthma / therapy*
  • Desensitization, Immunologic / adverse effects*
  • Humans
  • Hypersensitivity / epidemiology
  • Hypersensitivity / immunology
  • Hypersensitivity / therapy*
  • Incidence
  • Injections, Subcutaneous
  • Risk Factors
  • Surveys and Questionnaires

Substances

  • Allergens